Cingulate Inc. Increase (Decrease) in Other Receivables
Cingulate Inc. (CING) reported Increase (Decrease) in Other Receivables of $30.43 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherReceivables · last filed 2026-08-13
- Cingulate Inc. increase (decrease) in other receivables for the quarter ending 2026-06-30 was -$15.49K.
- Cingulate Inc. increase (decrease) in other receivables for the quarter ending 2026-03-31 was $45.92K, a 201.19% increase year-over-year.
- Cingulate Inc. increase (decrease) in other receivables for the quarter ending 2025-09-30 was -$544.00.
- Cingulate Inc. increase (decrease) in other receivables for the quarter ending 2025-06-30 was -$21.99K.
| Period end | Increase (Decrease) in Other Receivables 3 month | Increase (Decrease) in Other Receivables 6 month | Increase (Decrease) in Other Receivables 9 month |
|---|---|---|---|
| 2026-06-30 | -$15.49K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $30.43K 10-Q · filed 2026-08-13 | |
| 2026-03-31 | $45.92K 10-Q · filed 2026-05-14 | ||
| 2025-09-30 | -$544.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$22.53K derived: sum of 2 quarters · filed 2026-08-13 | -$7.28K 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$21.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$6.74K 10-Q · filed 2026-08-13 | |
| 2025-03-31 | $15.25K 10-Q · filed 2026-05-14 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | -$12.38K 10-Q · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | -$12.38K 10-Q · filed 2025-08-19 | |
| 2024-03-31 | -$12.38K 10-Q · filed 2025-05-08 | ||
| 2023-09-30 | -$29.63K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$228.60K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | -$198.96K 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |